Darunavir

2.1 Testing Prior to Initiation of darunavir tablets/ritonavir In treatment-experienced patients, treatment history, genotypic and/or phenotypic testing is recommended to assess drug susceptibility of the HIV-1 virus. Refer to Dosage and Administration, and for dosing recommendations. Appropriate laboratory testing such as serum liver biochemistries should be conducted prior to initiating therapy with darunavir tablets/ritonavir.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Co-administration of darunavir tablets/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below.

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with darunavir/ritonavir. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. Post-marketing cases of liver injury, including some fatalities, have been reported., Skin reactions ranging from mild to severe, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis, have been reported.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following adverse reactions are discussed in other sections of labeling: Hepatotoxicity, Severe Skin Reactions, Diabetes Mellitus/Hyperglycemia, Fat Redistribution, Immune Reconstitution Syndrome, Hemophilia Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions., The most common clinical adverse drug reactions to…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

5 products from 3 makers in the NepalDoc medicine catalog use this generic:

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Storage Store at 20°C to 25°C (68°F to 77°F); Keep darunavir tablets out of reach of children.

Storage information from the U.S. FDA-approved label.